Six of the patients, of whom four had non-renal SLE, had follow-up of at least 24 weeks. Of those, five showed dramatic ...

A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, ...

Intermountain Health is now offering a national first-of-its kind expansion of CAR-T Cell Therapy, bringing cutting-edge cancer care closer to patients in ...

The EBMT, the EHA, and the GoCART Coalition proudly announce the release of the second edition of the EU CAR-T Handbook, a ...

CAR-T cell therapy, which involves genetically engineered T-lymphocytes targeting cancer cells, has shown high efficacy in blood cancers and is being explored for solid tumors and autoimmune diseases.

Allogeneic CAR-T cell therapy is produced using CRISPR gene editing from cells donated by healthy individuals.

Illustration showing chimeric antigen receptor (CAR) T cells attacking kidney cancer cells. [Nemes Laszlo / Science Photo Library / Getty Images] Chimeric antigen receptor (CAR) T-cell therapy is ...

CAR-T therapy works by engineering a patient's T cells to recognize and destroy cancer cells. But the study found that CAR-T cells from aged mice had poor mitochondrial function, lower "stemness ...